In the past 30 years, Chengda International has developed from a traditional textile and apparel trading company into a value-added trading service provider with R&D and design, cutting-edge marketing, cross-border sourcing and logistics services. The company is headquartered in Dalian and has wholly owned subsidiaries in Shanghai and Tokyo.
With more than 200 domestic and overseas high-quality suppliers and direct marketing agencies in Southeast Asia with Bangladesh as the procurement fulcrum, Chengda International has strong cross-border procurement capability.
As a supply chain organizer and manager, we are committed to building a globally competitive trade service provider with annual sales of nearly RMB 2 billion and long-term service customers in more than 50 countries and regions, including Japan, North America, South America and Europe.
The company has 8 wholly-owned or holding subsidiaries and 5 shareholding companies, mainly engaged in supply chain (trade), medicine and medical care, financial investment, energy development, etc. The total annual profit peaked at 2.3 billion yuan, and the market value of the stock peaked at more than 60 billion yuan.
Founded in Dalian, China
Annual sales
Annual purchase volume
Business scope
Cotton and Woolen Products Import & Export Corporation, engaging in textile and garment import and export business.
the whole company was restructured into a joint-stock company, and renamed as Liaoning Chengda Company Limited with a registered capital of 50 million yuan.
and on August 19, 1996, the company was listed on the Shanghai Stock Exchange with the stock code 600739, and the registered capital was increased to 168 million yuan.
In January 1998, the company invested in Guangfa Securities Co., Ltd.
bio-pharmaceuticals, energy development and financial services with the original accumulation of textile and garment trade for many years.
was invested and established. Chengda Biological has become one of the most technologically complete vaccine R&D and production companies in China, and is currently the world's largest human rabies vaccine manufacturer.
was established as a holding subsidiary with a registered capital of RMB 60 million on the basis of the original main business of Liaoning Chengda - import and export trade of textile and garments.
In 2013, Chengda International introduced the advanced medical concept and production technology from Japan and entered into the medical and health field, and established the brand of Tomomi-Chengda Zhimei.
was established. In February 2015, Liaoning Chengda International Co.
In 2018, Chengda International integrated advanced technology from Japan and R&D resources from domestic universities to enter the field of new high-tech textile materials and established TecNature brand.
Supply
Medical
Financial
Energy